Personalized, adaptive deep brain stimulation (DBS) can enhance the control of motor symptoms of Parkinson's disease (PD) compared with standard DBS, new research suggests. In a blinded randomized ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adaptive ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...

This video is no longer available. Rick Schena, of Alexandria, Virginia, and his doctor at MedStar Health, in McLean, have begun using the latest technology — adaptive deep brain stimulation — in his ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's ...

Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in ...

Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...